NEWS
Will Congress Finally Act on Patent Thickets?
In 2019, the Committee moved legislation to prevent brand drug companies from amassing superfluous patents around their products—a strategy that, as we’ve written before, is uniquely problematic in the United States.
Federal Debt: The Baseline and Options for Reform
On May 13, experts convened at AEI to discuss the United States’ fiscal trajectory: how we got here, where we’re going, and what we can do to reduce the burden of debt for future generations.
Navigating the Upcoming Tax Cliff: Can Republicans Prevent a Tax Increase Without Adding to the Deficit?
On December 22, 2017, President Donald Trump signed into law the Tax Cuts and Jobs Act (TCJA).
Current and Future State of US Biosimilars
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Trends in the US Insulin Market: New Prices, New Players, New Dynamics
Insulin, a drug first developed more than 100 years ago, has experienced a surge in political interest in recent years following dramatic price hikes.
Implications of Cannabis Legalization for the US Federal Budget
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
When the TCJA Expires: A Tax Policy Summit
The Committee for a Responsible Federal Budget hosted “a tax policy summit “When the TCJA Expires: A Tax Policy Summit” on March 28, 2024.
Biden Budget Proposes a Step Toward Biologic Drug Competition
Politicians—Democrats and Republicans alike—regularly complain about high drug prices and the need for policy changes to make prescription medicines more affordable for patients (read: voters).
MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
In a newly released report, MGA highlights the broad economic impact of Otsuka in the United States.
MGA’s Alex Brill on CNBC’s Squawk Box Discussing Tackling the Tax Gap
Alex Brill joined CNBC’s “Squawk Box” to discuss the IRS’ attempt to crack down on the tax gap.
The Next Tax Fight: SALT
Much ink has been spilled either criticizing or praising the bipartisan, bicameral Wyden-Smith tax deal. The bill makes many retroactive and mostly temporary changes, when sound tax policy should generally be prospective and permanent.
Alex Brill on Single-Payer Health Care System and Drug Costs
Alex Brill is a senior fellow at the American Enterprise Institute (AEI), where he studies the impact of tax policy on the US economy as well as the fiscal, economic, and political consequences of tax, budget, health care, retirement security, and trade policies.
New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
In a new report, MGA examines the role of rebates among a subset of prescription drugs with the biggest price hikes between 2018 and 2023.
The Threat to Preferred Pharmacy Networks
Provider networks are a well-known tool health insurance companies use to keep down the cost of care.
Alex Brill mentioned on MSN
If the Supreme Court rules in their favor, it could open the door to reshaping the country’s tax code.
- The Child Tax Credit: Tradeoffs and Preferences
- Oregon’s Measure 118: The Turnover Tax Is the Worst
- Dueling Child Tax Credit Proposals: Harris vs. Vance
- Trump Proposes Bringing Back the Deduction for Auto Loan Interest
- Overtime Income Tax Break: Not Illogical, Just Costly and Complicated
- Presidential Candidates’ Dueling Child Credit Expansions Explained
- A Tip Exemption Is Not Sound Tax Policy
- Implications of Cannabis Legalization for the US Federal Budget
- Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
- A Balanced Plan for Fiscal Stability and Economic Growth
